

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-10: (Withdrawn)

Claim 11. (Currently Amended) A method of preventing or treating a ~~disorder characterized by amyloid deposition~~ Alzheimer's disease in a mammalian subject, comprising administering to the subject a dosage of ~~an agent~~ synuclein or a fragment thereof effective to produce an immune response comprising anti-synuclein antibodies against an amyloid component characteristic of said disorder and an adjuvant that augments the immune response to the synuclein, and thereby preventing or treating the disease.

Claims 12-14: (Canceled)

Claim 15. (Currently Amended) The method of claim ~~13~~ 11, wherein said ~~amyloid component~~ synuclein or fragment thereof is a ~~is selected from the group consisting of~~ AA, AL, ATTR, ApoA1, Alys, Agel, Acys, A β , AB₂M, ASer, Acal, A1APP and synuclein-NAC fragment.

Claims 16-17: (Canceled)

Claim 18. (Currently Amended) The method of claim ~~17~~ 11, wherein said administering ~~includes~~ further comprises administering ~~at least two amyloid fibril components~~ A β or a fragment thereof.

Claim 19. (Currently Amended) The method of claim 11, wherein said agent ~~is a peptide~~ synuclein or fragment thereof is linked to a carrier protein.

Claim 20. (Canceled)

Claim 21. (Currently Amended) The method of claim ~~20~~11, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum ~~and~~ Freund's adjuvant.

Claim 22. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum titer of the anti-synuclein antibodies of at least 1:1000 with respect to said ~~amyloid component~~ A β .

10
A
Claim 23. (Currently Amended) The method of claim 22, wherein said serum titer of the anti-synuclein antibodies is at least 1:5000 with respect to said ~~fibril~~ component A β .

Claim 24. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum ~~amount~~ titer of immunoreactivity anti- synuclein antibodies corresponding to greater than about four times higher than a serum ~~level~~ titer of immunoreactivity anti- A β antibodies of measured in a pre-treatment control serum sample.

Claim 25. (Original) The method of claim 24, wherein said serum ~~amount of~~ immunoreactivity titer of the antibodies is measured at a serum dilution of about 1:100.

Claims 26-57: (Canceled)
